Clinical Trial Update: Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the 13-valent pneumococcal conjugate vaccine in patients with end-stage renal disease; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Michigan State University | Conditions: End Stage Renal Disease | Phase 4 | Status: COMPLETED | Results posted: 2016-11-17